COST OF THERAPY INCURRED FOR TUBERCULOSIS PATIENTS RECEIVING DIRECTLY OBSERVED THERAPY (DOT)

  • Manjusha Sajith Assistant Professor, Department of Clinical Pharmacy, Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Pune, Maharashtra, India
  • Ansu Thomas Bharati Vidyapeeth University
  • Jaydeep J Kothia Bharati Vidyapeeth University
  • Bhumika Chandrakar Bharati Vidyapeeth University
  • Atmaram Pawar Bharati Vidyapeeth University
  • Medha Deepak Bargaje Bharati Vidyapeeth University

Abstract

Objective: To estimate the cost of therapy of tuberculosis patients registered under DOTS program in the treatment of tuberculosis.

Methods: A prospective observational study was conducted over a period of nine months in the Pulmonary Department of Bharati hospital and Research centre, Pune. 97 patients registered under RNTCP between August 2014 and April 2015, were interviewed at two time points: one at the time of first hospital visit and second on the completion of treatment. During the interview, information relating to various costs such as direct (out of pocket) and indirect cost was collected.

Results: The mean total cost for Pulmonary tuberculosis treatment was found to be/5474.7 ($85.4), Extra pulmonary was/10574.8 ($164.9) and Pulmonary and Extra pulmonary was/14638.5 ($228.3) respectively. Out of total cost the cost incurred by the patients for the hospital stay and diagnosis (i.e. tuberculosis detection) has the maximum expenditure cost which was 90.4 % for pulmonary tuberculosis, 77.2% extra pulmonary and 72.5% pulmonary and extra pulmonary. About 39.2 % of patients and their care takers lost work days. 52.0% pulmonary patients, 68.4% extra-pulmonary and 66.7 % pulmonary and extra-pulmonary patients had decreased earning ability due to illness.

Conclusion: The maximum cost is incurred for diagnosis and hospital stay in tuberculosis patients. Though DOTS strategy can help to reduce cost, achieve effective cure and save life of TB patients, still patients need to spend for other investigations and other drugs.

 

Keywords: Tuberculosis, DOTS, Patient cost

Downloads

Download data is not yet available.

References

1. Anunnatsiri S. “Factors associated with treatment outcomes in pulmonary tuberculosis in northeastern Thailand”. Southeast Asian J Trop Med Public Health 2005;36:324-30.
2. “Global Tuberculosis Report” World Health Organization; 2014. Available from: URL: http://www.who.int/tb/publications/ global_report/gtbr14_executive_summary. pdf. [Last accessed on 08 Jun 2015]
3. Bijoyeta Das. “In: Pictures: India’s drug-resistant TB crisis.” Al Jazeera, February 2014. Available from: URL: http://www.aljazeera.com/indepth/inpictures/2014/02/pictures-india-drug-resistant-tb--2014210100656564.html. [Last accessed on 08 Jun 2015]
4. About RNTCP.” TBC India. Available from: URL: http://www.tbcindia.nic.in/rntcp.htm. [Last accessed on 08 Jun 2015]
5. TK Ray, N Sharma, MM Singh, GK Ingle. “Expenses incurred by patients with tuberculosis prior to attending DOT centres.” Natl Med J India 2004;17:227–8.
6. Devra M Barter. “Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa–a systematic review”. BMC Public Health 2012;12:980.
7. M Muniyandi. “Costs to patients with tuberculosis treated under dots programme”. Indian J Tuberc 2005;52:188-96.
8. Gema Yolanda–Montes, Guzmán, Renata Heras Ovalles, Rafael Laniado. “Indirect patient expenses for antituberculosis treatment In Tijuana, Mexico: is treatment really free?” J Infect Dev Countries 2009;3:778-82.
9. Ramya Ananthakrishnan. “Expenditure pattern for TB treatment among patients registered in an urban government DOTS program in chennai city, South India”, Hindawi Publishing Corporation Tuberculosis. Res Treatment 2012:6. doi.org/10.1155/2012/747924. [Article in Press]
10. Russell S. “The economic burden of illness for households in developing countries. A review of studies focusing on malaria, tuberculosis and HIV/AIDS”. Am J Trop Med Hyg 2004;(2 Suppl):147-55.
Statistics
334 Views | 690 Downloads
How to Cite
Sajith, M., A. Thomas, J. J. Kothia, B. Chandrakar, A. Pawar, and M. D. Bargaje. “COST OF THERAPY INCURRED FOR TUBERCULOSIS PATIENTS RECEIVING DIRECTLY OBSERVED THERAPY (DOT)”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 11, Aug. 2015, pp. 141-4, https://innovareacademics.in/journals/index.php/ijpps/article/view/7862.
Section
Original Article(s)